Effects of adjuvants on IgG subclasses elicited by virus-like particles.
BACKGROUND
Virus-Like Particles (VLPs) represent an efficient strategy to present and deliver conformational antigens to the immune system, inducing both arms of the adaptive immune response. Moreover, their particulate structure surrounded by cell membrane provides an adjuvanted effect to VLP-based immunizations. In the present study, the elicitation of different patterns of IgG subclasses by VLPs, administered in CpG ODN1826 or poly(I:C) adjuvants, has been evaluated in an animal model.


RESULTS
Adjuvanted VLPs elicited a higher titer of total specific IgG compared to VLPs alone. Furthermore, while VLPs alone induced a balanced TH2 pattern, VLPs formulated with either adjuvant elicited a TH1-biased IgG subclasses (IgG2a and IgG3), with poly(I:C) more potent than CpG ODN1826.


CONCLUSIONS
The results confirmed that adjuvants efficiently improve antigen immunogenicity and represent a suitable strategy to skew the adaptive immune response toward the differentiation of the desired T helper subset, also using VLPs as antigen.
Lab, of Molecular Biology and Viral Oncogenesis, Istituto Nazionale Tumori Fond, G, Pascale, Naples-Italy.
Maria Luisa
ML
Visciano
Maria
M
Tagliamonte
Maria Lina
ML
Tornesello
Franco M
FM
Buonaguro
Luigi
L
Buonaguro
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D000918:Antibody Specificity / Q000187:drug effects / Q000276:immunology; D016764:Cell Polarity / Q000187:drug effects; D005260:Female; D015483:HIV Antibodies / Q000276:immunology; D015488:HIV Antigens / Q000276:immunology; D016655:HIV Core Protein p24 / Q000276:immunology; D015497:HIV-1 / Q000187:drug effects / Q000276:immunology*; D056724:Immunity, Humoral / Q000187:drug effects / Q000276:immunology; D007114:Immunization; D007074:Immunoglobulin G / Q000097:blood / Q000145:classification*; D007700:Kinetics; D051379:Mice; D008807:Mice, Inbred BALB C; D009838:Oligodeoxyribonucleotides / Q000494:pharmacology; D011070:Poly I-C / Q000494:pharmacology; D018417:Th1 Cells / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D018418:Th2 Cells / Q000187:drug effects / Q000276:immunology; D014771:Virion / Q000187:drug effects / Q000276:immunology*; D054299:env Gene Products, Human Immunodeficiency Virus / Q000276:immunology
D000276:Adjuvants, Immunologic; C408982:CPG-oligonucleotide; D015483:HIV Antibodies; D015488:HIV Antigens; D016655:HIV Core Protein p24; D007074:Immunoglobulin G; D009838:Oligodeoxyribonucleotides; D054299:env Gene Products, Human Immunodeficiency Virus; C097729:gp140 envelope protein, Human immunodeficiency virus 1; D011070:Poly I-C